Hexavalent Chromium Induces Malignant Transformation of Human Lung Bronchial Epithelial Cells Via ROS-Dependent Activation of miR-21-PDCD4 Signaling by Pratheeshkumar, Poyil et al.
University of Kentucky
UKnowledge
Center for Research on Environmental Disease
Faculty Publications Environmental Disease
6-13-2016
Hexavalent Chromium Induces Malignant
Transformation of Human Lung Bronchial
Epithelial Cells Via ROS-Dependent Activation of
miR-21-PDCD4 Signaling
Poyil Pratheeshkumar
University of Kentucky, pratheeshkumar.poyil@uky.edu
Young-Ok Son
University of Kentucky, young-ok.son@uky.edu
Sasidharan Padmaja Divya
University of Kentucky, divya.sp@uky.edu
Lilia Turcios
University of Kentucky, liliaturcios@uky.edu
Ram Vinod Roy
University of Kentucky, ramvroy.123@uky.edu
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/environmental_disease_facpub
Part of the Cancer Biology Commons, Disorders of Environmental Origin Commons, Oncology
Commons, and the Pharmacology, Toxicology and Environmental Health Commons
This Article is brought to you for free and open access by the Environmental Disease at UKnowledge. It has been accepted for inclusion in Center for
Research on Environmental Disease Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Pratheeshkumar, Poyil; Son, Young-Ok; Divya, Sasidharan Padmaja; Turcios, Lilia; Roy, Ram Vinod; Hitron, John Andrew; Wang,
Lei; Kim, Donghern; Dai, Jin; Asha, Padmaja; Zhang, Zhuo; and Shi, Xianglin, "Hexavalent Chromium Induces Malignant
Transformation of Human Lung Bronchial Epithelial Cells Via ROS-Dependent Activation of miR-21-PDCD4 Signaling" (2016).
Center for Research on Environmental Disease Faculty Publications. 4.
https://uknowledge.uky.edu/environmental_disease_facpub/4
Authors
Poyil Pratheeshkumar, Young-Ok Son, Sasidharan Padmaja Divya, Lilia Turcios, Ram Vinod Roy, John
Andrew Hitron, Lei Wang, Donghern Kim, Jin Dai, Padmaja Asha, Zhuo Zhang, and Xianglin Shi
Hexavalent Chromium Induces Malignant Transformation of Human Lung Bronchial Epithelial Cells Via ROS-
Dependent Activation of miR-21-PDCD4 Signaling
Notes/Citation Information
Published in Oncotarget, v. 7, no. 32, p. 51193-51210.
Licensed under a Creative Commons Attribution 3.0 License.
Digital Object Identifier (DOI)
https://doi.org/10.18632/oncotarget.9967
This article is available at UKnowledge: https://uknowledge.uky.edu/environmental_disease_facpub/4
Oncotarget51193www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 32
Hexavalent chromium induces malignant transformation of 
human lung bronchial epithelial cells via ROS-dependent 
activation of miR-21-PDCD4 signaling
Poyil Pratheeshkumar1,2,*, Young-Ok Son1,2,*, Sasidharan Padmaja Divya1,2, Lilia 
Turcios3, Ram Vinod Roy1,2, John Andrew Hitron1,2, Lei Wang1,2, Donghern Kim2, 
Jin Dai2, Padmaja Asha4, Zhuo Zhang2, Xianglin Shi1,2
1Center for Research on Environmental Disease, University of Kentucky, Lexington, KY, USA
2Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA
3Department of Surgery, University of Kentucky, College of Medicine, Lexington, KY, USA
4National Centre for Aquatic Animal Health, Cochin University of Science and Technology, Cochin, India
*These authors equally contributed to this work
Correspondence to: Xianglin Shi, email: xshi5@email.uky.edu
Keywords: hexavalent chromium, ROS, miR-21-PDCD4 signaling, IL-6, STAT3
Received: April 05, 2016    Accepted: May 20, 2016    Published: June 13, 2016
ABSTRACT
Hexavalent chromium [Cr(VI)] is a well-known human carcinogen associated 
with an increased risk of lung cancer. However, the mechanisms underlying Cr(VI)-
induced carcinogenesis remain unclear. MicroRNA-21 (miR-21) is a key regulator of 
oncogenic processes. Studies have shown that miR-21 exerts its oncogenic activity 
by targeting the tumor suppressor gene programmed cell death 4 (PDCD4). The 
present study examined the role of miR-21-PDCD4 signaling in Cr(VI)-induced 
cell transformation and tumorigenesis. Results showed that Cr(VI) induces ROS 
generation in human bronchial epithelial (BEAS-2B) cells. Chronic exposure to 
Cr(VI) is able to cause malignant transformation in BEAS-2B cells. Cr(VI) caused 
a significant increase of miR-21 expression associated with an inhibition of PDCD4 
expression. Notably, STAT3 transcriptional activation by IL-6 is crucial for the 
Cr(VI)-induced miR-21 elevation. Stable knockdown of miR-21 or overexpression of 
PDCD4 in BEAS-2B cells significantly reduced the Cr(VI)-induced cell transformation. 
Furthermore, the Cr(VI) induced inhibition of PDCD4 suppressed downstream 
E-cadherin protein expression, but promoted β-catenin/TCF-dependent transcription 
of uPAR and c-Myc. We also found an increased miR-21 level and decreased PDCD4 
expression in xenograft tumors generated with chronic Cr(VI)-exposed BEAS-2B 
cells. In addition, stable knockdown of miR-21 and overexpression of PDCD4 reduced 
the tumorogenicity of chronic Cr(VI)-exposed BEAS-2B cells in nude mice. Taken 
together, these results demonstrate that the miR-21-PDCD4 signaling axis plays an 
important role in Cr(VI)-induced carcinogenesis.
INTRODUCTION
Hexavalent chromium compounds [Cr(VI) 
compounds] have been classified as human carcinogens 
by the International Agency for Research on Cancer 
(IARC) of the World Health Organization (WHO) based 
on epidemiological studies results linking Cr(VI) to 
lung cancer [1]. Cr(VI) compounds are widely used in 
industries, such as plating, paint, steel, tanning, and chrome 
ore processing [2]. It has been reported that overproduction 
of reactive oxygen species (ROS) play a major role in 
Cr(VI)-induced carcinogenesis [3]. However, a detailed 
molecular mechanism of Cr(VI)–induced malignant 
transformation and tumorigenesis remains unknown.
MicroRNAs (miRNAs) are a novel class of 
endogenous, small, noncoding RNAs that negatively 
regulate approximately 30% of the gene expression by a 
site-specific interactions at the 3ʹ-UTR of target-mRNAs, 
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causing translational repression or degradation [4, 5]. 
Among them, miR-21 has emerged as a key onco-miR [6], 
since it is consistently overexpressed in a number of human 
malignancies [7–10]. Increased expression of miR-21 has 
been associated with a variety of processes including in 
carcinogenesis, apoptosis resistance, cell proliferation, 
tumor progression and chemoresistance [11–14]. A recent 
study suggests that NADPH oxidase-derived ROS is 
essential for the expression and function of miR-21 [15].
PDCD4 is a novel tumor suppressor reported 
to inhibit neoplastic transformation, tumor promotion 
and progression [4, 16, 17]. It has been established that 
miR-21 directly targets the 3′ UTR region of PDCD4 and 
down-regulates its expression [18–20]. Moreover, high 
miR-21 levels were found to be inversely correlated with 
PDCD4 expression in a variety of tumors [18–24]. PDCD4 
knockdown stimulated the invasion of colon cancer HT29 
cells and inhibited E-cadherin expression. The reduced 
levels of E-cadherin elicited an accumulation of active 
β-catenin in the nuclei with a reported stimulation of 
β-catenin/T cell factor (TCF)-dependent transcription of 
genes such as uPAR and c-Myc [25, 26].
Persistent activation of signal transducer and 
activator of transcription-3 (STAT3) is frequently 
associated with malignant transformation [27]. Recent 
studies implicate STAT3 as a vital regulator of microRNA 
(miRNA) expression, and in addition, the STAT3 signaling 
pathway is controlled by several specific miRNAs 
[28–31]. There are two phylogenetically conserved STAT3 
binding sites in miR-21 that regulate its oncogenic activity 
[30]. It has been reported that transcriptional activation 
of miR-21 by STAT3 leads to the induction of a stable 
transformed state in cancer cell lines [28]. Members of the 
IL-6 cytokine family are involved in a variety of biological 
responses, and the autocrine secretion of IL-6 contributes 
to cellular transformation via STAT3 phosphorylation [32].
In the present study, we investigated the interactive 
role of miR-21-PDCD4 signaling in Cr(VI)-induced 
malignant cell transformation. We found that chronic 
Cr(VI) exposure increased miR-21 levels and was 
associated with inhibition of PDCD4 expression and 
malignant cell transformation. Importantly, Cr(VI)-induced 
ROS was essential for the miR-21 elevation and PDCD4 
reduction. In addition, STAT3 transcriptional activation by 
IL-6 was crucial for the Cr(VI)-induced miR-21 elevation. 
Furthermore, PDCD4 reduction by Cr(VI) suppressed 
downstream protein E-cadherin expression, and led to the 
β-catenin/TCF-dependent transcription of uPAR and c-Myc. 
These results suggest that miR-21 and PDCD4 are critical 
components of Cr(VI)-induced malignant transformation.
RESULTS
Cr(VI) increases miR-21 and targets PDCD4
Earlier studies showed that PDCD4, a novel 
tumor suppressor is an important functional target of 
the oncogenic microRNA miR-21 [33]. In this study we 
first examined whether acute treatment with Cr(VI) can 
increase miR-21 expression and downregulate its target 
tumor suppressor protein PDCD4. We observed a dose-
dependent and significant (p < 0.05) elevation in the miR-
21 levels associated with a dose-dependent decrease in 
PDCD4 expression by RT-PCR and Western blot analysis 
respectively in human bronchial epithelial BEAS-2B 
cells treated with Cr(VI) (Figure 1A and 1B). Similar 
results were observed by immunofluorescence analysis 
of PDCD4, where acute treatment of Cr(VI) diminished 
the PDCD4 expression in the nucleus (Figure 1C). There 
was a significant decrease in the PDCD4 3ʹ-UTR reporter 
activity when cells were treated with 5 μM Cr(VI) for 6 h, 
whereas reporter activity was upregulated when miR-21 
gene expression was inhibited (Figure 1D). These results 
support the assumption that acute Cr(VI) treatment 
increases the miR-21 levels with an associated decrease 
in PDCD4 expression.
Cr(VI) regulates the downstream targets of 
PDCD4 -E-Cadherin, β-catenin and TCF4
Previous studies demonstrated that knock-down 
of PDCD4 down-regulates E-cadherin and increases 
β-catenin and TCF4 protein expression [26]. In the current 
study, acute treatment of BEAS-2B cells with Cr(VI) 
down-regulated E-cadherin protein expression with an 
associated up-regulation of active β-catenin (nuclear 
translocated form) and TCF4, whereas the level of total 
β-catenin remained unchanged (Figure 1E).
ROS generation is critical to effect an acute 
Cr(VI)-induced miR-21 –PDCD4 signaling 
cascade
A critical question for this investigation was whether 
Cr(VI)-induced ROS plays any role in miR-21 –PDCD4 
signaling. Cr(VI)-induced ROS production was quantified 
by flow cytometry using the fluorescent probes DHE 
and DCFDA. Cr(VI) exposure dramatically stimulated 
O2
.− and H2O2 generation in BEAS-2B cells, as indicated 
by an increase of DHE (Figure 2A–2C) and DCFDA 
(Figure 2E–2G) fluorescence intensity, respectively, when 
levels were compared to those generated from  untreated 
control cells. The DHE signal was increased by Cr(VI) and 
LY83853 (O2
.− donor) and inhibited by MnTMPyP, cell-
permeable SOD mimetic (O2
.− scavenger) (Figure 2D). 
Similarly, the DCFDA signal was increased by Cr(VI) and 
H2O2, and inhibited by CAT (H2O2 scavenger) (Figure 2H). 
The fluorescence intensity stimulated by Cr(VI) was also 
abolished by apocynin (APO), a NOX inhibitor. Further, 
the Cr(VI)-induced •OH generation in BEAS-2B cells was 
detected by Electron spin resonance (ESR) (Figure 2I). 
As shown in Figure 2J, Cr(VI) exposure induced a drastic 
increase in NOX activity within 6 h and lasted for up to 
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24 h. Moreover we found that acute Cr(VI) treatment 
also increased the expression of p47phox, one of the 
NOX subunits (Figure 2K). Taken together, these results 
suggest that Cr(VI) exposure induces ROS production in 
BEAS-2B cells, and activation of NOX is required for this 
ROS generation.
Next we sought the role of Cr(VI)-induced ROS 
generation in miR-21- PDCD4 signaling. As outlined 
above, we demonstrated that ROS plays an essential 
role in Cr(VI)-induced miR-21 elevation and PDCD4 
suppression. However, the Cr(VI)-induced miR-21 
elevation and PDCD4 suppression were markedly reversed 
by treatment with the ROS inhibitors, NAC or Catalase 
(Figure 2L–2M). These results provide solid evidence that 
ROS plays a key role in Cr(VI)-induced miR-21 elevation 
and PDCD4 reduction.
STAT3 binding to the miR-21 promoter upon 
IL-6 induction by Cr(VI)
Previous studies showed that Cr(VI) stimulates 
IL-6 mRNA levels and STAT3 phosphorylation in human 
airway epithelial cells [34]. STAT3 binding to the miR-21 
promoter upon IL-6 induction has been reported previously 
Figure 1: Cr(VI) increases miR-21 and targets PDCD4. BEAS-2B cells were exposed to increasing concentrations (0–5 μm) of 
Cr(VI) for 24 h. (A) The relative miR-21 level was determined by Taqman real-time PCR. (B) Immunoblot analysis of PDCD4 protein 
levels after acute Cr(VI) treatment. (C) Representative images of fluorescence immunostaining of PDCD4 (D) Cr(VI) increases the binding 
of miR-21 to the 3′-UTR of PDCD4. BEAS-2B cells were transfected with renilla reporter construct (pGL3-PDCD4_3ʹ-UTR), miR-21 
inhibitor (100 nM), negative control (100 nM), and pGL3-promoters and treated with 5 μM Cr(VI) for 6 h. Cellular lysates were subjected 
to a luciferase reporter analysis as described in Materials and Methods. The results are expressed as a relative activity (relative luminescence 
units (RLU)) normalized to the luciferase activity in the vector control cells without treatment. (E) Immunoblot analysis demonstrates that 
acute treatment of Cr(VI) decreases E-cadherin levels associated with an increase in β-catenin and TCF4 protein levels in BEAS-2B cells. 
Data presented in the bar graphs are the mean ± SD of three independent experiments. *indicates a statistically significant difference from 
control cells with p < 0.05. 
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[30]. To verify that IL-6 induces STAT3 binding to the 
miR-21 promoter after Cr(VI) treatment, we analyzed 
IL-6 levels and STAT3 activation by ELISA, and STAT3 
binding to the miR-21 promoter by ChIP assay. Acute 
Cr(VI) treatment to BEAS-2B cells significantly (p < 0.05) 
increased the IL-6 levels (Figure 3A), STAT3 activation 
(Figure 3B), and STAT3 phosphorylation (Figure 3C) in 
a dose-dependent manner. In addition, Cr(VI) treatment 
also increased the binding of STAT3 on miR-21 promoter 
(Figure 3D–3E). A genomic DNA fragment extending from 
−1120 to +25 bp relative to the miR-21 transcription start 
site containing the putative STAT3 enhancer region proved 
to be IL-6–responsive in a reporter assay [30]. As shown 
in Figure 3F, miR-21 promoter activity was significantly 
(p < 0.05) elevated by Cr(VI) or IL-6, while STAT3 knock 
down (siSTAT3) inhibited miR-21 promoter activity.
Figure 2: ROS generation is critical to effect an acute Cr(VI)-induced miR-21 –PDCD4 signaling cascade. 
Cr(VI) induces ROS generation. Generation of O2
.- and H2O2 were determined by staining the cells with DHE and DCFDA, respectively. 
BEAS-2B cells were exposed to Cr(VI) (0 to 5 µM) for 12 h and then were labeled with (A–C) DHE (10 µM) or (E–G) DCFDA (10 µM). 
Images were obtained by fluorescence microscopy and fluorescent intensity was determined by flow cytometry. BEAS-2B cells were 
exposed to Cr(VI) (0 or 5 µM) or were pretreated with MnTMPyP (5 µM; O2.- scavenger), CAT (1000 U/ml; H2O2 scavenger), or APO 
(50 µM; NOX inhibitor) for 2 h followed by Cr(VI) (5 µM) treatment for 6 h and then were labeled with (D) DHE (10 µM) or (H) DCFDA 
(10 µM) as described in the Materials and Methods section. LY83853 (10 µM) and H2O2 (0.1 mM) were used as positive controls for DHE 
and DCFDA measurements, respectively. (I) Generation of .OH was determined by ESR. (J) NOX activity was measured by the lucigenin 
chemiluminescence assay. (K) Cr(VI) increases the protein levels of NOX subunit, p47phox.  Exogenous addition of ROS inhibitors catalase 
or NAC inhibited the acute Cr(VI)- induced (L) miR-21 increase and (M) PDCD4 suppression. Data presented in bar graphs are the 
mean ± SD of three independent experiments. *and #indicate statistically significant differences compared to control without treatment or 
H2O2 /LY83853/ Cr(VI) treatment, respectively with p < 0.05.
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miR-21 elevation and PDCD4 suppression 
contribute to Cr(VI)-induced malignant cell 
transformation 
Chronic Cr(VI) exposure induces malignant 
transformation in BEAS-2B cells [3]. Malignant cell 
transformation was assessed by anchorage-independent 
growth in soft agar [35]. Long term (6 months) treatment 
with low concentrations (0.125, 0.25 and 0.5 μM) of 
Cr(VI) induced malignant transformation of BEAS-2B 
cells as shown by the marked increase in size and number 
of colonies compared to untreated control (Figure 4A–4B). 
A similar trend was observed with the clonogenic assay, 
where chronic Cr(VI) exposure to BEAS-2B cells showed 
a significant (p < 0.05) and dose-dependent increase in 
colony number (Figure 4C–4D).
We treated BEAS-2B cells with various 
concentrations (0.125, 0.25 and 0.5 μM) of Cr(VI) and 
measured the miR-21 levels and PDCD4 expression at 
two, four and six months. We found a dose-dependent 
and significant (p < 0.05) increase in the miR-21 levels 
(Figure 4E) associated with a dose-dependent and drastic 
decrease in the PDCD4 expression (Figure 4F) with 
chronic Cr(VI) exposure. Similar results were observed by 
immunofluorescence, when BEAS-2B cells were treated 
with Cr(VI) for six months and showed a marked decrease 
in the PDCD4 level (Figure 4G). These observations 
clearly emphasize a role for miR-21-PDCD4 signaling in 
Cr(VI)-induced transformation.
PDCD4 suppression by Cr(VI) down-regulates 
E-cadherin and increases the accumulation of  
β- catenin and TCF4 in the nucleus
Previous studies reported that suppression of PDCD4 
elicits an inhibition of E-cadherin expression, which 
is associated with an increase in β- catenin activation 
and TCF4 expression [26]. To evaluate this, we treated 
BEAS-2B cells with different concentrations of Cr(VI) 
for six months. As shown in Figure 5A, chronic Cr(VI) 
exposure resulted in decreased E-cadherin protein levels, 
while active β- catenin and TCF4 expressions increased, 
and these effects occurred in a dose-dependent manner. 
In confirmation, immunofluorescence analysis indicated 
that chronic Cr(VI) exposure decreased E-cadherin 
expression (Figure 5B) and increased β- catenin and TCF4 
accumulation in the nucleus (Figure 5C–5D). These data 
clearly show that chronic Cr(VI) exposure suppresses 
E-cadherin and increases the accumulation of β- catenin 
and TCF4 in the nucleus during malignant transformation.
Figure 3: STAT3 binding to the miR-21 promoter upon IL-6 induction by Cr(VI). BEAS-2B cells were treated with Cr(VI) 
(2.5 and 5 μM) for 24 h. Culture medium was collected to estimate the (A) IL-6 level using commercially available ELISA kit according 
to manufacturer’s recommendation. (B) STAT3 activity was measured in the nuclear fraction of cell lysates using ELISA following the 
manufacturer’s protocol. (C) Total cell lysates were prepared for Western blot analysis using specific antibodies against pSTAT3 and 
STAT3. (D–E) BEAS-2B cells were exposed with IL-6 or Cr(VI) for 30 minutes and subjected to a chromatin immunoprecipitation (ChIP) 
analysis using anti-STAT3 or IgG isotype control. Coimmunoprecipitated DNA was amplified by PCR with primers specific for the miR-21 
upstream enhancer. (F) Reporter gene assays were performed in BEAS-2B cells transfected either with a luciferase vector driven by the 
miR-21 promoter/enhancer alone (−) or in the presence of a vector encoding a small hairpin RNA silencing STAT3 expression (siSTAT3). 
Data presented in the bar graphs are the mean ± SD of three independent experiments. *indicates a statistically significant difference 
compared to control with p < 0.05.
Oncotarget51198www.impactjournals.com/oncotarget
PDCD4 suppression by Cr(VI) increases the 
expression of uPAR and c-Myc
The c-Myc oncogene plays a vital role at both early 
and late stages of carcinogenesis [36]. uPAR is involved 
in cancer cell invasion and significantly correlates to 
tumor aggressiveness and poor outcome [37]. It has been 
reported that uPAR and c-Myc are the target genes of 
β-catenin/TCF4 dependent transcription [26]. As shown in 
Figure 6A, chronic Cr(VI) exposure increased c-Myc and 
uPAR expressions in BEAS-2B cells in a dose-dependent 
manner. Similarly, the invasive potential of BEAS-2B 
cells under chronic Cr(VI)-exposure was also increased 
in correlation with uPAR expression (Figure 6B–6C). 
BEAS-2B cells treated with 0.5 µM Cr(VI) for 6 months 
showed a 3-fold increase for invasion compared to 
untreated control cells (Figure 6C). A previous study 
demonstrated that in PDCD4 knock down cells, β-catenin 
binds with TCF4 in the nucleus, with subsequent binding 
of β-catenin/TCF4 complex to the uPAR and c-Myc 
promoters [26]. To investigate this mechanism for Cr(VI)-
induced carcinogenesis, we performed ChIP analysis using 
a TCF4 antibody and primers that specifically amplify the 
β-catenin/TCF4 binding site on the promoters of uPAR 
(–308 to –302) and c-Myc (–452 to –446). As shown in 
Figure 6D–6E, association of the β-catenin/TCF4 complex 
to the uPAR and c-Myc promoters increased during 
chronic Cr(VI) treatment in a dose-dependent manner. 
These results indicate that PDCD4 suppression increases 
uPAR and c-Myc expressions, and also activates β-catenin/
Figure 4: Cr(VI)-induced miR-21 increase and PDCD4 suppression contribute to malignant cell transformation. 
BEAS-2B cells were maintained in a medium containing various concentrations of Cr(VI) (0.125, 0.25 and 0.5 µM) for 6 months. (A–B) 
Cells were cultured in 0.35% soft agar for 5 weeks. The number of colonies in the entire dish was counted. (C–D) Cells (300 cells) from 
indicated Cr(VI) treatments were seeded into each of three dishes (60 mm diameter), and grown for an additional 10 days and stained with 
crystal violet. Colony numbers in the entire dish were counted. (E) The relative miR-21 level was determined by Taqman real-time PCR. 
(F) PDCD4 protein levels after chronic Cr(VI) treatment was detected by immunoblot analysis. The three panels show data obtained at 2, 
4 and 6 months of treatment. (G) Representative images of fluorescence immunostaining for PDCD4. Data presented in the bar graphs are 
the mean ± SD of three independent experiments. *indicates a statistically significant difference compared to control with p < 0.05.
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TCF4 complex binding to the uPAR and c-Myc promoters 
during chronic Cr(VI) exposure. 
Stable knockdown of miR-21 and overexpression 
of PDCD4 inhibit Cr(VI)-induced malignant cell 
transformation and invasion
To determine the oncogenic role of miR-21 in 
Cr(VI)-induced malignant transformation and invasion, 
BEAS-2B cells with stable knocked down of miR-21 were 
treated with Cr(VI) (0.5 μM) for six months. As shown in 
Figure 7A, miR-21 knock down cells showed no increase 
in miR-21 levels even after chronic Cr(VI) treatment. 
BEAS-2B cells with miR-21 knock down also blocked the 
suppression of its target tumor suppressor, PDCD4 that 
normally occurs with chronic Cr(VI) treatment (Figure 
7B). Importantly, miR-21 knock down significantly 
inhibited the chronic Cr(VI)-induced malignant cell 
transformation (Figure 7C) and invasion (Figure 7D). 
Similarly over-expression of PDCD4 (Figure 7E) in 
BEAS-2B cells significantly (p < 0.05) decreased the 
chronic Cr(VI)-induced malignant cell transformation 
(Figure 7F) and invasion (Figure 7G). These results 
demonstrated that the increased levels of oncomiR 
Figure 5: PDCD4 suppression by Cr(VI) down-regulates E-cadherin and increases the accumulation of β- catenin 
and TCF4 in the nucleus. BEAS-2B cells were maintained in a medium containing various concentrations of Cr(VI) (0.125, 0.25 and 
0.5 µM) for 6 months. (A) Total cell lysates were prepared for Western blot analysis using specific antibodies against E-Cadherin, Active-
β-catenin, β-catenin, TCF4 and GAPDH. Representative images of fluorescence immunostaining of (B) E-cadherin (C) β- catenin and 
(D) TCF4. 
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miR-21 and suppression of tumor suppressor PDCD4 are 
critically important for Cr(VI)-induced malignant cell 
transformation and invasion.
Antioxidants inhibit chronic Cr(VI)-induced 
miR-21 elevation and PDCD4 suppression 
To investigate the role of antioxidants on 
chronic Cr(VI)-induced miR-21 elevation and PDCD4 
suppression, we treated BEAS-2B cells overexpressing 
catalase with Cr(VI) (0.5 μM) for six months. Our 
study shows that overexpression of catalase noticeably 
decreased the miR-21 elevation induced by chronic 
Cr(VI) treatment (Figure 7H) and suppressed the PDCD4 
reduction (Figure 7I) in BEAS-2B cells with chronic 
Cr(VI) treatment. Furthermore, catalase overexpression 
also decreased the chronic Cr(VI)-induced malignant 
cell transformation (Figure 7J) and invasion (Figure 7K). 
These observations clearly demonstrate the indispensable 
role of ROS in regulating miR-21-PDCD4 signaling during 
chronic Cr(VI)-induced malignant cell transformation and 
invasion.
Elevated miR-21 and suppressed PDCD4 
expression in Cr(VI)-exposed animals and 
xenograft tumors 
To explore whether Cr(VI) exposure causes miR-
21 elevation and PDCD4 suppression in vivo, BALB/c 
mice were nasally exposed to insoluble Cr(VI) particles 
(1.2 mg/ml) for up to 3 months. The results show that 
chronic Cr(VI) exposure at 1.2 mg/ml induced an increase 
in miR-21 levels (Figure 8A) and decreased PDCD4 
expression (Figure 8B–8C) in mouse lung tissue compared 
to control. Next we investigated tumorogenicity in nude 
mice using BEAS-2B cells chronically exposed to Cr(VI). 
For this study, nude mice were injected sc with BEAS-
2B cells that had been exposed to Cr(VI) for 6 months 
at the indicated concentration. Over a 4-week period post 
inoculation, we observed visible tumor formation that 
increased progressively in size for mice injected with 
Cr(VI)-treated BEAS-2B cells but not in those injected 
with control cells (Figure 8D–8E). Consistent with our 
in vitro findings above, we found significantly increased 
miR-21 levels (Figure 8F) associated with decreased 
Figure 6: PDCD4 suppression by Cr(VI) increases the expression of uPAR and c-Myc. BEAS-2B cells were exposed to 
various concentrations of Cr(VI) (0.125, 0.25 and 0.5 µM) for 6 months. (A) Expression levels for uPAR and c-Myc were analyzed by 
Western blot. To evaluate invasive capacity (B–C) 1 × 105 cells from each group were seeded on the top chamber of 24-well plate culture 
inserts coated with 20 μl of matrigel in duplicate. Cells were cultured for additional 48 h. Invaded cells on the bottom of insert were stained 
and quantified. (D–E) For the ChIP assay, TCF4 binding regions on uPAR and c-Myc promoters were identified. Chromatin isolated from 
chronic Cr(VI) exposed BEAS-2B cells were immunoprecipitated with an anti-TCF4 antibody or control mouse IgG. The TCF4 binding 
to the uPAR and c-Myc promoters was analyzed by RT PCR with specific primers. Data presented in the bar graphs are the mean ± SD of 
three independent experiments. *indicates a statistically significant difference compared to control with p < 0.05.
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PDCD4 expression (Figure 8G) in xenograft tumors 
generated with chronic Cr(VI) exposed BEAS-2B cells. 
In addition we also demonstrated that stable knockdown 
of miR-21 or overexpression of PDCD4 in BEAS-2B cells 
chronically exposed to Cr(VI) reduced tumorogenicity 
in nude mice. For these studies, BEAS-2B cells stably 
expressing miR-21 shRNA, PDCD4, or vector, with or 
without Cr(VI) exposure for 6-month, were injected to 
nude mice. Four weeks after injection, tumor development 
was assessed. Tumors developed from BEAS-2B cells 
with stable knockdown of miR-21 and exposed to Cr(VI) 
(Figure 8H), and tumors formed from Cr(VI)-exposed 
BEAS-2B cells overexpressing PDCD4 (Figure 8I) were 
smaller than those of Cr(VI)-exposed-vector cells. To 
confirm these results, we examined the basal levels of 
miR-21 and PDCD4 in a variety of lung cancer cell lines. 
Our results showed increased miR-21 levels (Figure 8J) 
and decreased PDCD4 expression (Figure 8K) in the lung 
cancer cells (H2030, H460, H23, and A549) compared to 
normal lung epithelial cells (BEAS-2B and NL-20).
The levels of miR-21 increase and PDCD4 
decrease in human lung adenocarcinoma tissue
The expression levels of miR-21 and its downstream 
target protein PDCD4 were determined by real time PCR 
and florescence immunohistochemistry respectively 
in lung tissues from lung adenocarcinoma patients. As 
shown in Figure 9A, there was a 6-fold increase in miR-
21 level in lung cancer tissues compared to the normal 
Figure 7: Stable knockdown of miR-21 and overexpression of PDCD4 or catalase inhibit Cr(VI)-induced malignant 
cell transformation and invasion. (A–D) BEAS-2B cells were stably knockeddown with miR-21 shRNA or their corresponding 
vehicle vector and exposed to Cr(VI) (0 or 0.5 µM) for 6 months. (A) the relative miR-21 level was determined by Taqman real-time PCR. 
(B) Cell lysates were prepared to determine the protein level of PDCD4 using Western blot analysis. (C) Anchorage-independent colony 
growth was assessed as previously described. (D) Cell invasion was assessed as described previously (E-G) BEAS-2B cells were stably 
overexpressed with PDCD4 or their corresponding vehicle vector and exposed with Cr(VI) (0 or 0.5 µM) for 6 months. (E) Cell lysates 
were prepared to determine the protein level of PDCD4 by Western blot analysis. (F) Anchorage-independent colony growth and (G) cell 
invasion were assessed as previously described. (H-K) BEAS-2B cells were stably overexpressed with catalase or their corresponding 
vehicle vector and exposed with Cr(VI) (0 or 0.5 µM) for 6 months. (H) The relative miR-21 level was determined by Taqman real-
time PCR. (I) PDCD4 protein levels after chronic Cr(VI) treatment was detected by immunoblot analysis. (J) Anchorage-independent 
colony growth and (K) cell invasion were assessed as previously described. Data presented in the bar graphs are the mean ± SD of three 
independent experiments. * indicates a statistically significant difference compared to control with p < 0.05.
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tissues from same patients. However, the expression 
levels of PDCD4 were decreased in all lung cancer tissues 
when compared with normal tissues as determined by 
florescence immunohistochemistry (Figure 9B). Moreover, 
phosphorylated STAT3 was also increased in lung tumor 
tissues of patients (Figure 9C). These results demonstrate 
the indispensable role of the miR-21-PDCD4 signaling 
axis in lung carcinogenesis.
DISCUSSION
Occupational exposure to Cr(VI) is a well-
established cause of lung cancer [38–41], therefore, 
Cr(VI) is considered a class I carcinogen [42]. Several 
studies have shown that ROS generated by Cr(VI) 
exposure is one of the major causes of carcinogenesis 
[3, 45, 43, 44]. Although Cr(VI) is a well-established 
carcinogen, relatively little is known about the molecular 
mechanisms of Cr(VI)-induced malignant transformation. 
In this study we detail a mechanism for Cr(VI)-induced 
malignant transformation and the involvement of a 
miR-21-PDCD4 signaling process.
MicroRNA’s (miRs) are important post-
transcriptional regulators that influence more than 30% of 
human mRNAs. Significant changes in microRNA (miR) 
expression in response to environmental exposure in 
humans have recently been reported [46, 47]. Notably miR-
21, a key oncogene, plays an important role in the initiation 
and progression of cancer [47] and is highly overexpressed 
in most cancers [48, 49]. miR-21 binds to the 3′-UTR of 
Figure 8: Increased miR-21 and suppressed PDCD4 expression in Cr(VI)-exposed animals and xenograft tumors. 
(A–C) Female BALB/c mice were treated intranasally with either insoluble Cr (VI) (1.2 mg/ml) or PBS (vehicle control), once a day, 5 days/
week. After 3 months, mice were euthanized using CO2 and lung tissue was isolated for further examination. (A) The relative miR-21 level 
was determined by Taqman real-time PCR. PDCD4 protein expression was detected by (B) immunohistochemistry and (C) immunoblot 
analysis. (D–G) Nude mice were injected sc with BEAS-2B cells exposed to indicated concentration of Cr(VI) for 6 months. After 4 weeks, 
mice were euthanized using CO2 and tumor was isolated for further examination. (D–E) Tumor volume was measured and (F) the relative 
miR-21 level was determined by Taqman real-time PCR. (G) PDCD4 protein expression was detected by immunohistochemistry. (H-I) 
Inhibition of in vivo tumor growth in nude mice with miR-21 knockdown and PDCD4 overexpression in chronic Cr(VI)-exposed BEAS-2B 
cells. BEAS-2B cells with (H) miR-21 knockdown, (I) PDCD4 overexpression and respective vector controls were exposed to Cr(VI) (0 or 
0.5 μM) for 6 months, xenograft growth of tumors in nude mice was performed as described previously. (J–K) Different lung cancer cell 
lines were used to determine the basal levels of (J) miR-21 and (K) PDCD4 expression. Data presented in the bar graphs are the mean ± SD 
of three independent experiments. * indicates a statistically significant difference compared to control with p < 0.05.
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the tumor suppressor PDCD4 to suppress its translation [4]. 
Down-regulation of PDCD4 expression by miR-21 leads to 
tumor cell growth, survival, chemoresistance, invasion and 
metastasis [4, 50]. Inhibition of miR-21 or overexpression 
of PDCD4 results in decreased tumor formation and 
growth [51]. Therefore, miR-21 and PDCD4 are potential 
targets for novel cancer prevention and therapeutics. In our 
preliminary analysis, we found increased miR-21 levels 
and decreased PDCD4 expressions in lung cancer cell lines 
(H2030, H460, H23, and A549) compared to those found 
in normal lung epithelial cells (BEAS-2B and NL-20). 
We investigated the effect of Cr(VI) on the interaction of 
miR-21-PDCD4 signaling and subsequent malignant cell 
transformation; both acute and chronic treatments of Cr(VI) 
induce miR-21 increases with an associated suppression 
of PDCD4. Cr(VI) also increased the binding of miR-21 
to the 3′-UTR of PDCD4. Moreover, the increased miR-
21 and reduced PDCD4 levels brought about by chronic 
Cr(VI) treatments in BEAS-2B cells also induced malignant 
transformation. Furthermore, stable shut down of miR-
21 and overexpression of PDCD4 in BEAS-2B cells 
significantly inhibited the chronic Cr(VI)-induced malignant 
transformation. These results strongly demonstrate that this 
interactive miR-21-PDCD4 signaling plays an important 
role in Cr(VI)-induced malignant transformation.
We also explored the mechanisms by which Cr(VI) 
activates miR-21. STAT3, known to be important for 
cancer initiation and tumor progression, was reported to 
bind directly to the miR-21 promoter upon IL-6 induction 
[28, 30, 52]. In our study treatment of BEAS-2B cells with 
Cr(VI) significantly increased IL-6 secretion. In addition 
Cr(VI) also triggered STAT3 transcriptional activation 
and phosphorylation. Furthermore, the binding of STAT3 
on the miR-21 promoter was also increased with Cr(VI) 
treatment. These data clearly suggest that Cr(VI)-induced 
IL-6 secretion mediates STAT3 activation, which is crucial 
for the rise in miR-21.
Studies suggest that hydrogen peroxide (H2O2) 
can up-regulate miR-21 levels and decrease PDCD4 
expression in vascular smooth muscle cells [53]. It is 
also established that Cr(VI)-induced ROS is crucial to 
malignant cell transformation [3]. However, the role 
of Cr(VI)-induced ROS in miR-21-PDCD4 signaling 
and malignant transformation is currently unclear. We 
demonstrated that Cr(VI) induces ROS and that p47phox, 
one of the NOX subunits is the key source Cr(VI)-induced 
ROS. Moreover, exogenous treatment of cells with catalase 
or NAC significantly inhibited the Cr(VI)-induced a rise 
in miR-21 and decreased PDCD4 levels. To substantiate 
a role for antioxidants in the Cr(VI)-induced malignant 
cell transformation mediated by increased miR-21 levels 
and PDCD4 suppression, we chronically treated BEAS-2B 
cells overexpressing catalase with Cr(VI) for six months. 
Interestingly, catalase overexpression in BEAS-2B cells 
significantly inhibited Cr(VI)-induced miR-21 elevation, 
PDCD4 suppression and malignant cell transformation.
A disturbance in epithelial cell adhesion, which 
leads to a more invasive and metastatic phenotype, is a 
hallmark of tumor progression [54]. E-cadherin, a well-
known primary transmembrane glycoprotein molecule 
is involved in Ca2+ -dependent cell–cell adhesion 
in epithelial tissues. Several studies report a strong 
correlation between E-cadherin loss and the initiation and 
progression of tumors [26, 54]. The cytoplasmic domain 
of E-cadherin is attached to actin microfilaments via two 
other molecules, α- and β-catenin [55]. Disruption of these 
E-cadherin homotypic interactions results in the release of 
β -catenin from E-cadherin and subsequent translocation 
of β -catenin into the nucleus; the nuclear β-catenin 
associates with TCF4 (a member of transcription factor 
family) to form a β-catenin/TCF complex and activates 
the transcription of genes involved in cancer initiation, 
progression and metastasis such as c-Myc, and uPAR 
[26]. Down-regulation of PDCD4 leads to an inhibition 
of E-cadherin expression, which is  associated with an 
increase in β- catenin/TCF4 dependent transcription 
[26]. In our study both acute and chronic treatment 
with Cr(VI) suppressed the E-cadherin expression, and 
was accompanied by an increased active β- catenin and 
TCF4 expression in BEAS-2B cells in a dose-dependent 
manner. In addition, chronic Cr(VI) exposure increased 
uPAR and c-Myc protein expressions in BEAS-2B cells, 
as well as their invasive potential. Furthermore, chronic 
Cr(VI) exposure increased the binding of TCF4 on 
uPAR and c-Myc promoters in BEAS-2B cells. These 
findings indicate that PDCD4 suppression is critical for 
the β-catenin/TCF dependent transcription of c-Myc, and 
uPAR in Cr(VI)-induced carcinogenesis.
To explore whether Cr(VI) exposure causes miR-
21 elevation and PDCD4 suppression in vivo, BALB/c 
mice were nasally exposed to insoluble Cr(VI) particles 
for 3 months. We found an increase in miR-21 levels 
associated with PDCD4 suppression in the lungs of mice 
exposed to Cr(VI). Moreover, we found an significantly 
increased miR-21 levels associated with decreased PDCD4 
expression in xenograft tumors generated with chronic 
Cr(VI) exposed BEAS-2B cells.  In addition we confirmed 
that stable knockdown of miR-21 or overexpression of 
PDCD4 reduce the tumorigenicity of chronic Cr(VI) 
exposed BEAS-2B cells in nude mice. Similar results were 
observed in lung adenocarcinoma tissues from patients 
compared with normal tissues from same patients.
In summary, we found that chronic Cr(VI) exposure 
increases miR-21 levels with an associated inhibition of 
PDCD4 expression, and cause malignant transformation 
in BEAS-2B cells. Cr(VI) triggers the miR-21 increase 
via the IL-6/STAT3 pathway. Cr(VI)-induced PDCD4 
suppression down-regulates the E-cadherin protein 
expression along with an upregulation of active β-catenin 
(nuclear translocated form) and TCF4 in BEAS-2B cells. 
In addition, Cr(VI) exposure increases uPAR and c-Myc 
expressions, and also activates β-catenin/TCF4 complex 
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binding to the uPAR and c-Myc promoters. Stable 
knockdown of miR-21 or overexpression of PDCD4 
reduces the tumorogenicity of chronic Cr(VI) exposed 
BEAS-2B cells in nude mice (Figure 9D). In short, our 
findings demonstrate an indispensable role for an miR-21-
PDCD4 signaling axis in Cr(VI)-induced malignant cell 
transformation and lung carcinogenesis.
MATERIALS AND METHODS
Antibodies and chemicals
Potassium dichromate (K2Cr2O7), apocynin 
(APO), 5,5-dimethyl-1-pyrroline-1-oxide (DMPO), 
were purchased from Sigma-Aldrich (St Louis, MO). 
Both Dichlorodihydrofluoresceine acetate (DCFDA) and 
dihydroethidium (DHE) were purchased from Molecular 
Probes (Eugene, OR). Manganese(III) tetrakis(1-methyl-
4-pyridyl) porphyrin (MnTMPyP) was purchased from 
Cayman Chemical (Ann Arbor, MI). Human miR-21 
hairpin inhibitor was purchased from Thermo Fisher 
Scientific Dharmacon (Chicago, IL, USA). Antibodies 
against PDCD4 (CST#9535), E-cadherin (CST#3195), 
β-catenin (CST#8480), c-Myc (CST#5605), uPAR 
(CST#9692), pSTAT3 Tyr705 (CST#9145) and STAT3 
(CST#9139) were purchased from Cell Signaling 
Technology (Danvers, MA). Anti–active-β-catenin 
(clone 8E7#05-665) antibody was purchased from EMD 
Millipore (Billerica, MA). Antibodies against TCF4 
(sc-13027) and GAPDH (sc-25778) were purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
Cell lines and cell culture
Human bronchial epithelial cell lines BEAS-2B, 
NL20 and other lung cancer cell lines H2030, H460, H23, 
A549 cells were obtained from the American Type Culture 
Collection (Rockville, MD). Chromium transformed cells 
Figure 9: The levels of miR-21 and PDCD4 in lung adenocarcinoma. Lung adenocarcinoma tissues from patients was used 
to demonstrate the (A) relative miR-21 level compared to normal tissue from same patients. (B) PDCD4 protein expression was detected 
by immunofluorescence and (C) STAT3 phosphorylation was determined by immunohistochemistry. Data presented in the bar graphs 
are the mean ± SD of three independent experiments. *indicates a statistically significant difference compared to control with p < 0.05. 
(D) Proposed mechanism of Cr(VI)-induced malignant cell transformation and carcinogenesis.
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(CrT) were generated as described previously [45]. NL20 
cells were grown at 37°C in humidified air containing 
5% CO2 in serum-free LHC-9 medium. BEAS-2B and 
CrT cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM), while H2030, H460, H23, and A549 
cells were cultured in RPMI 1640 supplemented with 
10% fetal bovine serum (FBS), 2 mM L-glutamine, 
and 5% penicillin/streptomycin at 37°C in a humidified 
atmosphere with 5% CO2 in air. 
K2Cr2O7 was used for Cr(VI) treatments. For short-
term exposure of Cr(VI), cells were grown to 80–90% 
confluent, and then the medium was replaced with DMEM 
medium containing 0.1% FBS for overnight before 
Cr(VI) treatment at the dose and duration indicated. In 
some experiments, cells were first pretreated with various 
inhibitors for 2 h and then exposed to Cr(VI). For chronic 
exposure of Cr(VI), the cells were continuously cultured in 
growth medium with the indicated concentration Cr(VI).
Plasmids and transfection
Plasmid DNA encoding human catalase and STAT3 
shRNA were purchased from Origene (Rockville, MD). 
PDCD4 3′-UTR reporter plasmid was kindly provided by 
Dr. Yong Li (University of Louisville, USA). The STAT3-
miR-21 reporter was constructed as described previously 
[30]. PcDNA3.1/PDCD4 plasmid was kindly provided by 
Dr. Hsin-Sheng Yang (University of Kentucky, USA).
The overexpression of catalase or PDCD4 and 
knockdown of STAT3 in BEAS-2B cells were performed 
using Lipofectamine™2000 (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s protocol. Briefly, BEAS-
2B cells were seeded at approximately 50% confluency in 
6-well culture plates and transfected with 4 μg plasmid. 
Cell clones resistant to G418 were isolated; overexpression 
of CAT and PDCD4 protein production were confirmed by 
immunoblotting.
The pLenti-III-miR-Off-has-miR-21-puro-GFP 
expression vector and the negative control vector pLenti-
III-miR-Off- puro-GFP were purchased from Applied 
Biological Materials, Inc. (Richmond, CA). Human 
embryonic kidney 293T cells (ATCC, Manassas, VA) 
were transfected with lentiviral packaging vectors (ABM, 
Richmond, BC, CA) and lentiviral vectors expressing 
miR-Off-has-miR-21-puro-GFP or miR-Off- puro-GFP 
by Lipofectamine™2000 (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s protocol [56].
For generating stable miR-21 knockdown cell 
lines, two days after transfection, supernatants containing 
viral particles were harvested and used to infect BEAS-
2B cells at approximately 70% confluence in DMEM 
supplemented with 8 μg/ml of polybrene using lentifectin 
reagent (ABM technologies) following the manufacture’s 
protocol. 72 h after transfection, the medium was changed 
to the selection DMEM with 10% FBS and supplemented 
with puromycin 1 μg/mL (sigma) to screen stable cell 
lines for further assay. Three weeks later, the cell clones 
were screened and further cultured in DMEM medium 
containing 1 µg/mL puromycin and selected through 
FACS (Fluorescent Assisted Cell Sorting system). 
Intracellular ROS determination
H2O2 and O2.- generations were examined using 
the fluorescent dye DCFDA and DHE, respectively, 
as described previously [45]. The cells were cultured 
in 6-well plates (2 × 105 cells/well), treated with 5 μM 
of Cr(VI) for 12 h and incubated with DCFDA or DHE 
(10 μM) for 40 min at 37°C. Trypsinized cells were washed 
twice with cold PBS, and analyzed by fluorescence-
activated cell sorting (FACS Calibur, BD Biosciences). 
The fluorescence intensity of DCFDA was measured at an 
excitation wavelength of 492 nm and an emission wave 
length of 517 nm. The fluorescence intensity of DHE was 
measured at an excitation wavelength of 535 nm and an 
emission wavelength of 610 nm.
Electron spin resonance (ESR) assay
ESR measurement was conducted using a Bruker 
EMX spectrometer (Bruker Instruments, Billerica, MA) 
and a flat cell assembly. The intensity of ESR signal 
was used to measure the amount of hydroxyl radical 
generation. DMPO was used as a spin or radical trap. 
DMPO was charcoal purified and distilled to remove all 
ESR detectable impurities before use. Hyperfine couplings 
were measured (to 0.1 G) directly from magnetic field 
separation using potassium tetraperoxochromate (K3CrO8) 
and 1,1-diphenyl-2-picrylhydrazyl (DPPH) as reference 
standards. Reactants were mixed in test tubes to a total 
final volume of 0.5 mL. The reaction mixture was then 
transferred to a flat cell for ESR measurement.
Clonogenic assay
BEAS-2B cells (105 cells) were seeded into each 
well of a 6-well plate and allowed to attach overnight. 
After the indicated exposure, cells were collected by 
trypsinization, three hundred cells were then reseeded 
into each of three dishes (60 mm diameter), and grown for 
10 days. The cells were fixed with 2% formalin for 10 min 
and stained with 0.5% crystal violet stain and counted.
NOX activity assay
NOX activity was measured by the lucigenin 
enhanced chemiluminescence method as described 
previously [3]. Briefly, cells were harvested and 
homogenized by sonication in cold lysis buffer (20 mM 
KH2PO4, pH 7.0, 1 mM EGTA, 1 mM phenyl methyl 
sulfonyl fluoride, 10 µg/ml aprotinin, and 0.5 µg/ml 
leupeptin). Homogenates were centrifuged at 800 × g at 
4°C for 10 min to remove the unbroken cells and debris, 
and aliquots were used immediately. To start the assay, 
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100-µl of homogenate supernatants were added to 900 µl 
of 50 mM phosphate buffer, pH 7.0, containing 1 mM 
EGTA, 150 mM sucrose, 5 µM lucigenin, and 100 µM 
NADPH. Photon emission in terms of relative light units 
was measured in a Glomax luminometer (Promega) every 
30 s for 5 min. There was no measurable activity in the 
absence of NADPH. Superoxide anion production was 
expressed as relative chemiluminescence (light) units 
(RLU)/mg protein.
Luciferase reporter assay
BEAS-2B cells transfected with the luciferase 
reporter constructs were seeded into 24-well plates 
(5 × 104/well) and subjected to various treatments when 
cultures reached 80–90% confluence. Cellular lysates 
were subjected to a luciferase reporter assay (Promega, 
Madison, WI) using Glomax luminometer (Promega) as 
described previously [45]. The results are expressed as 
relative activity normalized to the luciferase activity in the 
control cells without treatment.
ELISA for IL-6 and STAT3
BEAS-2B cells were cultured in DMEM 
supplemented with 10% FBS containing Cr(VI) (0, 2.5, 
and 5 µM) for 24 h. Subsequently, the culture media 
was collected and used to estimate IL-6 level using 
commercially available IL-6 ELISA kit (BioLegend, 
Inc. CA, USA) according to the manufacturers’ 
recommendation.
For quantitative analysis of STAT3, TransAM ELISA 
kit (Active Motif, Carlsbad, CA) was used following 
the manufacturer’s protocol. For this assay, the nuclear 
extracts of cell samples from various treatment groups 
were prepared using the Nuclear Extraction kit (Active 
Motif) according to the manufacturer’s direction. 
Absorbance was recorded at 450 nm with reference taken 
at 650 nm. The assay was performed in duplicate and the 
results are expressed as the percentage absorbance of 
control group.
Anchorage-independent colony growth assay for 
Cr(VI)-induced cell transformation
Soft agar colony formation assay was performed as 
described previously [45]. BEAS-2B cells or BEAS-2B 
cells with stable overexpression of catalase or PDCD4 
or BEAS-2B cells with stable knockdown of miR-21 
were treated with 0.5 µM Cr(VI). The fresh medium was 
added every 3 days. After 24 weeks, 1 × 104 cells were 
suspended in 3 mL culture medium containing 0.35% 
agar and seeded into 6-well plates with 0.5% agar base 
layer, and maintained in an incubator for 4 weeks. The 
colonies greater than 0.1 mm in diameter were scored by 
microscopic examination.
The Cr(VI)-transformed cells from anchorage-
independent colonies were selected and grown in DMEM. 
Passage-matched cells without Cr(VI) treatment were used 
as control.
Collagen matrix invasion assay
Collagen matrix invasion assay was performed 
as described previously [57]. Briefly, BEAS-2B cells 
(105 cells/Transwell) chronically exposed to Cr(VI) 
were seeded to the top chamber of invasion chamber and 
incubated 24 h. Cells in top chamber (non-invaded) were 
removed, and cells on bottom of filter insert (invaded) 
were fixed with 3.7% paraformaldehyde and stained 
with 0.5% crystal violet in 2% ethanol. Membranes were 
washed and the dye was eluted with 10% acetic acid. 
Absorbance was measured at 595 nm using a microtiter 
plate reader (Beckman coulter). The number of invaded 
cells was presented relative to untreated controls. 
Experiments was performed in duplicate and repeated 
3 times.
Chromatin immunoprecipitation (ChIP) assay
ChIP analysis was performed using a PierceTM 
Agarose ChIP Kit (Thermo Scientific, Rockford, IL). 
Sheared chromatin was diluted and immunoprecipitated 
with 2 μg of anti-STAT3, anti-TCF4 or control IgG 
antibody. DNA protein complexes were eluted from the 
protein A/G agarose beads using a spin column and were 
reverse cross-linked by incubating with NaCl at 65°C. The 
relative TCF4 binding to the c-MYC and uPAR promoters 
or STAT3 binding to miR-21 promoter was analyzed by 
MyiQ™ Single-Color Real-Time PCR Detection System 
(Bio-Rad, Hercules, CA) with SYBR Green PCR master 
mix using following primer sequences, TCF4 binding to 
c-Myc promoter: (F) GCGCCCATTAATACCCTTCT and 
(R) TCTCCCTTTCTCTGCTGCTC; TCF4 binding to 
uPAR promoter: (F) GGAAGCAAAGCAAGGGTTAAG 
and (R) GCCCTGACTCATGGAGTTGT; STAT3 binding 
to miR-21 promoter/enhancer (F) CCTCTGAGAAG 
AGGGGACAA and (R) ACCGCTTCCAGCA 
AAAGAGT. General PCR amplification also performed 
in a Mastercycler® thermal cycler (Eppendorf, Foster City, 
CA).
Quantitative real-time polymerase chain reaction 
(qRT-PCR)
Total RNA was extracted using Trizol (Invitrogen), 
and cDNA was synthesized by using TaqMan® microRNA 
reverse transcriptase kit (Applied Biosystems, Foster City, 
CA, USA) according to the manufacturer recommendations. 
Expression of miR-21-microRNA was determined by 
the TaqMan miRNA-assay (Applied Biosystems, Foster 
City, CA, USA), and normalized using the 2−ΔΔCT -method 
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relative to U6-snRNA. All TaqMan-PCR reactions were 
performed in triplicates using a Bio-Rad’s MyiQTM single-
color real-time PCR detection system.
Human tissue samples
Human lung adenocarcinoma tissue (stage IA or 
IIA) was provided from the Biospecimen and Tissue 
Procurement Shared Resource Facility of the University 
of Kentucky Markey Cancer Center. Lung tissues were 
freshly frozen and fixed with 10% formalin for real-time 
PCR and immunofluorescence analysis, respectively. 
Western blot analyses
Cells lysates were prepared in ice-cold RIPA buffer 
(Sigma-Aldrich) containing freshly added protease 
inhibitor cocktail. The lysate was then centrifuged at 
12000 g for 10 min at 4°C and the supernatant (total cell 
lysate) was collected, aliquoted and stored at −80°C. The 
protein concentration was determined using Coomassie 
Protein Assay Reagent (Thermo, Rockford, IL). About 
40 μg cellular proteins were separated using 6%–12% 
SDS-polyacrylamide gel and transferred to nitrocellulose 
membrane (Bio-Rad, Hercules, CA). Membranes were 
blocked with 5% fat-free dry milk in 1X Tris-buffered 
saline (TBS) and incubated with antibodies. Protein bands 
were detected by incubating with horseradish peroxidase-
conjugated antibodies (Kirkegaard and Perry Laboratories, 
Gaithersburg, MD) and visualized with enhanced 
chemiluminescence reagent (Perkin Elmer, Boston, MA). 
Tumor tissues were homogenized with MagNA Lyser 
Green Beads using MagNA Lyser Instrument (Roche, 
Indianapolis, IN) and Western blot analysis performed.
Chronic exposure of animals to Cr(VI) particle
6–8 weeks old, female BALB/c mice were 
purchased from Jackson Laboratory (Bar Harbor, MN). 
Endotoxin-free basic zinc chromate particle was crushed 
using mortar and pestle and then washed with distill water 
and acetone to generate a particle of 4.7 μm and a purity of 
99–100%. Cr(VI) particle was suspended in sterile 0.9% 
sodium chloride solution at a concentration of 1.2 mg/ml 
and prepared as previously described [58]. Animals under 
a light anesthesia (isoflurane) were intranasally exposed 
to a 50 μl dose of chromate or saline once a week up to 
12 weeks. Lungs of animals were isolated and subject to 
freshly frozen and 10% formalin fixation for real time 
PCR and immunohistochemistry analysis, respectively. 
Tumorigenesis studies
Athymic nude mice (NU/NU, 6–8 weeks old; 
Charles River) were housed in a pathogen-free room 
in the animal facilities at the Chandler Medical Center, 
University of Kentucky. Cells (2 × 106 cells per mouse) 
from different treatments were resuspended in serum-free 
medium with matrigel basement membrane matrix (BD 
Biosciences) at a 1:1 ratio (total volume = 100 μl) and 
subcutaneously injected into the flanks of nude mice. 
Mice were checked daily for tumor appearance, and tumor 
volume was measured every 3 days for 30 days. Tumor 
volume was determined by Vernier caliper, following the 
formula of A × B2 × 0.52, where A is the longest diameter 
of tumor and B is the shortest diameter. At the end of the 
experiment, mice were sacrificed, the tumors excised and 
snap frozen.
Immunohistochemical staining
Five-μm thick frozen tumor sections were hydrated 
in phosphate buffered saline (PBS), and non-specific 
binding sites were blocked with 10% horse serum in 
PBS. Staining was performed using Vectastain ABC 
Kit according to the manufacturer’s protocol (Vector 
Laboratories, Burlingame, CA). Briefly, the sections 
were incubated with rabbit anti-PDCD4 (1:100) antibody 
for 2 h at room temperature, washed and then incubated 
with biotinylated secondary antibody for 45 min followed 
by incubation with ABC reagent. After washing in PBS, 
color was developed with DAB solution until the desired 
staining intensity was achieved. Finally, the sections were 
counterstained with hematoxylin.
Immunofluorescence analysis
BEAS-2B cells or BEAS-2B cells chronically 
exposed to Cr(VI) were grown on coverslips in 6-well 
plates and treated with Cr(VI). The cells were fixed in 
4% paraformaldehyde followed by permeabilization 
with 0.2% Triton X-100, blocked with 10% horse serum 
in PBS solution, and incubation with antibodies PDCD4 
(1:500), E-cadherin (1:100), β-Catenin (1:100), TCF4 
(1:100) in buffer A (1% BSA, 0.1% Triton X-100, 10% 
horse serum in PBS solution) for 1 h at 37°C. The cells 
were then incubated with Alexa Fluor 594 goat anti-rabbit 
or Alexa Fluor 488 goat anti-rabbit secondary antibody 
and mounted using DAPI. The cells were visualized using 
digital confocal microscopy (Confocal Fluorescence 
Imaging Microscope, Leica TCS-SP5) or Olympus BX53 
fluorescence microscope.
For the formalin-fixed lung tissue fluorescence 
immunohistochemical analysis, air-dried tissue sections 
were rinsed, blocked, and incubated with primary 
antibody overnight. Second antibody was added for 
1 h. 300 μl of the diluted DAPI solution was added and 
incubated 2–5 min at room temperature. DAPI binds 
to DNA and is a convenient nuclear counterstain. The 
sections were mounted with an anti-fade mounting media. 
Olympus BX53 fluorescence microscope was used for 
visualization.
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Statistical analysis
Presented values are means ± SD. One-way analysis 
of variance (ANOVA) was used for statistical analysis, 
with p < 0.05 was considered significantly different.
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